Sentrian develops a clinical decision-support tool that applies biosensors and machine learning to detect deterioration across multiple chronic conditions and reduce false positives. The platform monitors conditions simultaneously and personalizes alert parameters to account for interactions between conditions. It is device-agnostic and favors passive monitors such as patches and mattress-based sensors; the company cites examples like a Withings sleep monitor pad. The software surfaces contextualized patterns so clinicians can set parameters rather than continuously review raw sensor data. Sentrian offers the service on a subscription basis and is targeting health systems, accountable care organizations, and Medicare Advantage plans. It is running two one-year payer pilots: Caremore (Wellpoint) with 2,000 COPD patients (1,000 device / 1,000 control) and a New York payer testing 500 device / 500 control. The company raised $12M to bring the product to market.

Total raised

$12M

Funding rounds

2

Latest round

Series A

Latest activity

Nov 2014